Business

Tetraphase wins FDA’s fast-track status

Tetraphase Pharmaceuticals Inc., a Watertown biotech that helped ignite a wave of initial public offerings when it went public a year ago, said Wednesday it has won fast-track designation from the Food and Drug Administration to develop an antibiotic to treat urinary tract infections.

The fast-track status is awarded to speed up the study and regulatory review of drugs that fight serious or life-threatening conditions. It will also allow Tetraphase executives to communicate more intensively with FDA regulators during the drug’s clinical trials.

Advertisement

“We find it encouraging because it shows the FDA recognizes the product is important and addresses an unmet medical need,” said Tetraphase chief executive Guy Macdonald. He cited the rise in multidrug-resistant bacteria, calling for new antibiotics.

Macdonald said Tetraphase is on track to complete clinical trials and file a new drug application with the FDA at the end of next year.

Get Business Headlines in your inbox:
The Globe's latest business headlines delivered every morning, Monday through Friday.
Thank you for signing up! Sign up for more newsletters here

The fast-track designation means the company would be likely to get a decision from the regulatory agency in mid-2016.

Robert Weisman

Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.